<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343547</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP16001104</org_study_id>
    <nct_id>NCT04343547</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults</brief_title>
  <official_title>A Randomized, Open Label, Single/Multiple Dose, Crossover Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate drug-drug interaction by comparing the
      pharmacokinetics (PK)/pharmacodynamics (PD), safety, and tolerability of single/multiple
      doses of DWP16001 , DWC202001 and DWC202002 alone or in combination in healthy male adults.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of DWP16001</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Peak Plasma Concetration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of DWP16001</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of DWC202001 and DWC202002</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Peak Plasma Concetration at steady-state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss of DWC202001 and DWC202002</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Area under the plasma concentration versus time curve at Tau, steady-state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of DWP 16001, DWC202001 and DWC202002</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Time at Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of DWP 16001, DWC202001 and DWC202002</measure>
    <time_frame>0-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of DWC202001 and DWC202002</measure>
    <time_frame>0-72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001</intervention_name>
    <description>Tablets, Oral, once daily single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWC202001+DWC202002</intervention_name>
    <description>Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001+DWC202001+DWC202002</intervention_name>
    <description>Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination</description>
    <arm_group_label>Experimental 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male adults ≥ 19 and ≤ 50 years of age at the time of the screening procedure

          2. 55.0 kg ≤ body weight ≤ 90.0 kg and 18.0 ≤ body mass index (BMI) ≤ 27.0

          3. Voluntarily decided to participate in the study and provided written consent prior to
             the screening procedure after receiving a detailed explanation on this study and fully
             understanding the information

          4. Is eligible to participate in the study at the discretion of the investigator by a
             physical examination, laboratory test, and medical history questionnaire, etc.

        Exclusion Criteria:

          1. Presence or prior history of a clinically significant hepatic, renal, nervous,
             respiratory, endocrine, hematologic and oncologic, cardiovascular, urogenital,
             psychiatric disorder

          2. Presence or prior history of a gastrointestinal disorder (e.g., gastrointestinal
             ulcers, gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease,
             etc.), or prior history of gastrointestinal surgery (except for simple appendectomy or
             hernia surgery) that may affect the safety and PK/PD assessment of the study drug.

          3. Hypersensitivity to, or history of clinically significant hypersensitivity to drugs
             including DWP16001 and other drugs of the same class (SGLT2 inhibitors), drugs
             including gemigliptin and other drugs of the same class, metformin and other drugs
             (aspirin, antibiotics, etc.)

          4. Considered ineligible for the study by the investigator for reasons including
             laboratory test results
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin Hyun Choi</last_name>
    <phone>82-02-550-8406</phone>
    <email>jhchoi413@daewoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

